Emrusolmin

Emrusolmin is an experimental drug for the treatment of neurodegenerative diseases. It is an inhibitor of protein aggregation, particularly preventing the aggregation of α-synuclein which is implicated in the development of Parkinson's disease. Other proteins it inhibits the aggregation of include tau which is associated with Alzheimer's disease and tauopathy, and amyloid beta which is associated with AD.
It is currently in clinical trials for Parkinson's disease and multiple system atrophy.